Cargando…

Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials

COVID-19 vaccines from multiple manufacturers are needed to cope with the problem of insufficient supply. We did two single-center, randomised, double-blind, placebo-controlled phase 1 and phase 2 trials to assess the safety, tolerability and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Meng, Fan-Yue, Gao, Fan, Jia, Si-Yue, Wu, Xiang-Hong, Li, Jing-Xin, Guo, Xi-Ling, Zhang, Jia-Lu, Cui, Bo-Pei, Wu, Zhi-Ming, Wei, Ming-Wei, Ma, Zhi-Long, Peng, Hai-Lin, Pan, Hong-Xing, Fan, Lin, Zhang, Jing, Wan, Jiu-Qin, Zhu, Zhong-Kui, Wang, Xue-Wen, Zhu, Feng-Cai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281021/ https://www.ncbi.nlm.nih.gov/pubmed/34267185 http://dx.doi.org/10.1038/s41392-021-00692-3

Ejemplares similares

Immunogenicity and safety of a new hexavalent rotavirus vaccine in Chinese infants: A randomized, double-blind, placebo-controlled phase 2 clinical trial
por: Wu, Zhi-Wei, et al.
Publicado: (2023)

Immunogenicity and safety of a severe acute respiratory syndrome coronavirus 2 inactivated vaccine in healthy adults: randomized, double-blind, and placebo-controlled phase 1 and phase 2 clinical trials
por: Pan, Hong-Xing, et al.
Publicado: (2021)

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial
por: Zhu, Feng-Cai, et al.
Publicado: (2020)

Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial
por: Shu, Ya-Jun, et al.
Publicado: (2021)

Safety and Immunogenicity of a Recombinant Tetanus Vaccine in Healthy Adults in China: A Randomized, Double‐Blind, Dose Escalation, Placebo‐ and Positive‐Controlled, Phase 1/2 Trial
por: Xu, Xiaowei, et al.
Publicado: (2021)

Safety and immunogenicity of a recombinant interferon-armed RBD dimer vaccine (V-01) for COVID-19 in healthy adults: a randomized, double-blind, placebo-controlled, Phase I trial
por: Zhang, Jikai, et al.
Publicado: (2021)

Construction and immunogenicity of a recombinant fowlpox vaccine coexpressing S1 glycoprotein of infectious bronchitis virus and chicken IL-18
por: Chen, Hong-Ying, et al.
Publicado: (2010)

Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial
por: Feng, Guang-Wei, et al.
Publicado: (2023)

A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase II Trial of Allisartan Isoproxil in Essential Hypertensive Population at Low-Medium Risk
por: Li, Ying, et al.
Publicado: (2015)

Safety and immunogenicity of an Escherichia coli-produced bivalent human papillomavirus type 6/11 vaccine: A dose-escalation, randomized, double-blind, placebo-controlled phase 1 trial
por: Mo, Zhao-Jun, et al.
Publicado: (2022)

Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial
por: Zhu, Ming-Huan, et al.
Publicado: (2022)

Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial
por: Chen, Gui-Ling, et al.
Publicado: (2022)

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
por: Huang, Xiaoyuan, et al.
Publicado: (2023)

First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial
por: Song, Yan, et al.
Publicado: (2023)

Famitinib versus placebo in the treatment of refractory metastatic colorectal cancer: a multicenter, randomized, double-blinded, placebo-controlled, phase II clinical trial
por: Xu, Rui-Hua, et al.
Publicado: (2017)

Targeting liquid-liquid phase separation in pancreatic cancer
por: Ming, Yue, et al.
Publicado: (2019)

Safety and immunogenicity evaluation of recombinant BCG vaccine against respiratory syncytial virus in a randomized, double-blind, placebo-controlled phase I clinical trial
por: Abarca, Katia, et al.
Publicado: (2020)

Safety and Immunogenicity of the GamTBvac, the Recombinant Subunit Tuberculosis Vaccine Candidate: A Phase II, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study
por: Tkachuk, Artem P., et al.
Publicado: (2020)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
por: Guo, Wanshen, et al.
Publicado: (2021)

Pharmacodynamic, pharmacokinetic, and phase 1a study of bisthianostat, a novel histone deacetylase inhibitor, for the treatment of relapsed or refractory multiple myeloma
por: Zhou, Yu-bo, et al.
Publicado: (2021)

Phase III randomized, placebo‐controlled, double‐blind study of monosialotetrahexosylganglioside for the prevention of oxaliplatin‐induced peripheral neurotoxicity in stage II/III colorectal cancer
por: Wang, De‐shen, et al.
Publicado: (2019)

Effects of Prior Influenza Exposure on Immunogenicity of Influenza Vaccine
por: Cao, Jia-Qian, et al.
Publicado: (2020)

Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study
por: Yu, Hui Jing, et al.
Publicado: (2023)

Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein
por: Yuan, Xiaomin, et al.
Publicado: (2015)

KEOPS complex promotes homologous recombination via DNA resection
por: He, Ming-Hong, et al.
Publicado: (2019)

Temporal Genetic Dynamics of an Invasive Species, Frankliniella occidentalis (Pergande), in an Early Phase of Establishment
por: Yang, Xian-Ming, et al.
Publicado: (2015)

Immunogenicity and safety of a recombinant adenovirus type-5 COVID-19 vaccine in adults: Data from a randomised, double-blind, placebo-controlled, single-dose, phase 3 trial in Russia
por: Lioznov, Dmitry, et al.
Publicado: (2023)

A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients
por: Xu, Dao-Zhen, et al.
Publicado: (2008)

Efficacy and safety of Shexiang Baoxin pill (MUSKARDIA) in patients with stable coronary artery disease: a multicenter, double-blind, placebo-controlled phase IV randomized clinical trial
por: Ge, Jun-Bo, et al.
Publicado: (2021)

The C-terminal low-complexity domain involved in liquid–liquid phase separation is required for BRD4 function in vivo
por: Wang, Chenlu, et al.
Publicado: (2019)

Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trial
por: Jin, Peng-Fei, et al.
Publicado: (2023)

Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial
por: Zhang, Yuemiao, et al.
Publicado: (2022)

Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials
por: Yang, Shilong, et al.
Publicado: (2021)

Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials
por: Zhu, Fengcai, et al.
Publicado: (2022)

Correction: A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients
por: Xu, Dao-Zhen, et al.
Publicado: (2008)

Correction: A Randomized Controlled Phase IIb Trial of Antigen-Antibody Immunogenic Complex Therapeutic Vaccine in Chronic Hepatitis B Patients
por: Xu, Dao-Zhen, et al.
Publicado: (2008)

ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial
por: Hu, Yue, et al.
Publicado: (2023)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial
por: Xia, Shengli, et al.
Publicado: (2021)

Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and multi-arm randomised, phase 1 trial
por: Gui, Yu-Zhou, et al.
Publicado: (2023)

A randomized, double-blind, placebo-controlled, dose-escalating phase I trial to evaluate safety and immunogenicity of a plant-produced, bivalent, recombinant norovirus-like particle vaccine
por: Leroux-Roels, Isabel, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_jauguirjco6n1lbb979uinp4dr